A1H Stock Chart & Stats
€0.68
€0.03(4.75%)
At close: 4:00 PM EDT
€0.68
€0.03(4.75%)
Day’s Range― - ―
52-Week Range€0.60 - €1.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€48.93M
Enterprise Value€67.72M
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,817,220
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Biological Technology PlatformAmoéba has a defined proprietary biological platform rather than a single conventional chemical product. Willaertia magna and its derivatives can support multiple agricultural applications, creating a foundation for product development and potential differentiation over the medium term.
Multiple Monetization ChannelsThe business model offers several ways to monetize the same underlying technology, including product sales, licensing, royalties, and collaborative development. This breadth could improve commercial flexibility as regulatory approvals and partner-led market access develop.
Narrower Losses And Improved Free Cash FlowThe reduction in losses from the 2023 level and improvement in free cash flow versus 2024 provide limited evidence of operational progress. If maintained, this direction could reduce the pace of financial deterioration, even though profitability and cash generation are not yet sustainable.
Bears Say
Revenue CollapseRevenue effectively disappearing in 2025 indicates that commercial traction is currently insufficient to support the operating model. Without recurring product, licensing, or partnership receipts, the company has limited internal funding capacity and remains exposed to delays in market adoption.
Persistent Deep LossesA long record of substantial operating and net losses shows that the platform has not yet translated into sustainable earnings. Continued negative margins can consume capital, restrict investment choices, and make future growth dependent on successful commercialization or additional funding.
Fragile Balance Sheet And Cash BurnNegative equity, materially higher debt, and ongoing negative free cash flow leave Amoéba with limited financial flexibility. The combination increases refinancing and external-funding dependence, potentially constraining development investment and weakening resilience if commercialization takes longer.
Amoeba SA News
A1H FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest stock price was €0.60 and its highest was €1.20 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €48.93M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Sep 24, 2026 which is in 15 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Mar 26, 2026. The company reported -€0.066 earnings per share for the quarter.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 77,817,220 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.066 in its last earnings report. Following the earnings report the stock price went down -1.62%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in DE:A1H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.